Growth Hormone Releasing Peptide -2 vial

GHRP-2 vial

Name:  Growth Hormone Releasing Peptide-2 vial / GHRP-2 vial

Form:  Sterile Filtered White lyophilized (freeze-dried) powder.

Dosage:  5mg/vial

Top color: Usually Black / blue / green / golden. 

Inventory: 10000 vials for sell.

MOQ: 100 vials

Package:  10vials/kit. 10kits/bag/carton 

Pack material: Shockproof film, shockproof envelope, and Cartons.  

Logo:  with or without both ok. 

OEM: Offer OEM service. Customed dosage & brand & LOGO & package & top color. OEM MOQ 100kits (=1000vials)

Shipment: By express to buyers’ door. 100% make sure delivery. 

Payment: TT/ Western Union/BTC/ETV/VISA and so on, please contact by email. 

Shipment time: Within three working days after payment. Usually need ten days to arrive buyers’ address. Resend if lost.

DESCRIPTION

GH-releasing peptides (GHRPs) are synthetic peptides that like GHRH act directly on pituitary somatotrophs to stimulate GH release. GHRP-2, an investigational drug, is one of the most potent members of the GHRP family. It has been shown to be effective in adults via the oral and intranasal as well as the iv route of administration.

GHRP-2 is a synthetic agonist of ghrelin, the newly-discovered gut peptide which binds to the growth hormone (GH) secretagogue receptor. Ghrelin has been shown to have two major effects, stimulating both GH secretion and appetite/meal initiation. GHRP-2 has been extensively studied for its utility as a growth hormone secretagogue (GHS). Animal studies have shown its effect on food intake. However, whether GHRP-2 can also stimulate appetite in humans when administered acutely is not known. We subcutaneously infused 7 lean, healthy males with GHRP-2 (1μg/kg/h) or saline for 270 minutes and then measured their intake of an ad libitum, buffet-style meal. Similar to what has been reported for ghrelin administration, our subjects ate 35.9±10.9 % more when infused with GHRP-2 vs. saline, with every subject increasing their intake even when calculated per kg body weight (136.0±13.0 kJ/kg vs 101.3±10.5 kJ/kg, p=0.008). The macronutrient composition of consumed food was not different between conditions. As expected, serum GH levels rose significantly during GHRP-2 infusion (AUC 5550±1090 μg/L/240 min vs. 412±161 μg/L/240 min, p=0.003). These data are the first to demonstrate that GHRP-2, like ghrelin, increases food intake, suggesting that GHRP-2 is a valuable tool for investigating ghrelin effects on eating behavior in humans.

Ghrelin, the recently identified peptide secreted by gastric endocrine cells (1), has attracted much interest for its dual effects. This endogenous ligand for the growth hormone secretagogue receptor (GHS-R) which was cloned in 1996 (2) regulates growth hormone (GH) release (3). Ghrelin also appears to play a role in the regulation of food intake and energy balance. When administered either centrally or peripherally to rodents, ghrelin increases food intake and body weight (4,5). Interestingly, its effects on food intake are independent of GH secretion (4,6-8) and appear to be mediated via the NPY/Agouti gene-related protein (AGRP) neurons in the hypothalamic arcuate nucleus (9,10). Peripheral ghrelin administration has recently been shown to stimulate food intake in lean, healthy men and women (11) and in cancer patients (12).

Data suggest that circulating ghrelin is also implicated in meal to meal regulation. Ghrelin levels increase in anticipation of a meal (13) and are suppressed by food ingestion (13, 14), but the underlying mechanisms are not known. The meal-related suppression of ghrelin is proportional to the carbohydrate (CHO) content of the meal but does not appear to be directly related to glucose or insulin (14,15), although insulin administration decreases ghrelin (16).

Serum ghrelin levels vary as a function of energy balance. Ghrelin levels are increased in anorexia (17) and decreased in obesity (18). Thus, it is possible that ghrelin may be an important player in food intake behavior and perhaps in chronic over- and undernutrition as well (19). Because of its dual effects, ghrelin may be a critical hormonal signal of nutritional status to the somatotropic axis, playing a role in integrating energy balance with the growth process (20).

Ghrelin is not available for long-term studies in human subjects in the United States, however, the synthetic GHS-R agonist GHRP-2 (DalaDßNalAlaTrpDPheLysNH2) is available for clinical studies. GHRP-2 belongs to a family of GHS(s) discovered in the 1980's and extensively studied for their effect on GH release (21). Despite the very different chemistry of natural ghrelin and synthetic GHS, evidence strongly and increasingly supports that they have the same biological actions. Like ghrelin, GHS(s) increase food intake and body weight in rodents (22). GHRP-2 has been shown to increase appetite ratings in children with idiopathic GH treated chronically with oral GHRP-2 (23).

The aim of this study was to investigate whether GHRP-2 stimulates food intake in healthy human subjects. Similar to the study by Wren et al. (11) which used ghrelin, we tested the effect of a short-term subcutaneous (sc) infusion of GHRP-2 on food intake during a buffet meal.

If OVERDOSE is suspected

If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.

Consumer information use

• If your symptoms or health problems do not get better or if they become worse, call your doctor.

• Do not share your drugs with others and do not take anyone else's drugs.

• Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.

• Throw away unused or expired drugs. Do not flush down a toilet or pour down a drain unless you are told to do so. Check with your pharmacist if you have questions about the best way to throw out drugs. There may be drug take-back programs in your area.

• Some drugs may have another patient information leaflet. Check with your pharmacist. If you have any questions about nandrolone, please talk with your doctor, nurse, pharmacist, or other health care provider.

• If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened

Warnings

PELIOSIS HEPATIS, A CONDITION IN WHICH LIVER AND SOMETIMES SPLENIC TISSUE IS REPLACED WITH BLOOD-FILLED CYSTS, HAS BEEN REPORTED IN PATIENTS RECEIVING ANDROGENIC ANABOLIC STEROID THERAPY. THESE CYSTS ARE SOMETIMES PRESENT WITH MINIMAL HEPATIC DYSFUNCTION, BUT AT OTHER TIMES THEY HAVE BEEN ASSOCIATED WITH LIVER FAILURE. THEY ARE OFTEN NOT RECOGNIZED UNTIL LIFE-THREATENING LIVER FAILURE OR INTRA-ABDOMINAL HEMORRHAGE DEVELOPS. WITHDRAWAL OF DRUG USUALLY RESULTS IN COMPLETE DISAPPEARANCE OF LESIONS. LIVER CELL TUMORS ARE ALSO REPORTED. MOST OFTEN THESE TUMORS ARE BENIGN AND ANDROGEN-DEPENDENT, BUT FATAL MALIGNANT TUMORS HAVE BEEN REPORTED. WITHDRAWAL OF DRUG OFTEN RESULTS IN REGRESSION OR CESSATION OF PROGRESSION OF THE TUMOR. HOWEVER, HEPATIC TUMORS ASSOCIATED WITH ANDROGENS OR ANABOLIC STEROIDS ARE MUCH MORE VASCULAR THAN OTHER HEPATIC TUMORS AND MAY BE SILENT UNTIL LIFE-THREATENING INTRA-ABDOMINAL HEMORRHAGE DEVELOPS. BLOOD LIPID CHANGES THAT ARE KNOWN TO BE ASSOCIATED WITH INCREASED RISK OF ATHEROSCLEROSIS ARE SEEN IN PATIENTS TREATED WITH ANDROGENS AND ANABOLIC STEROIDS. THESE CHANGES INCLUDE DECREASED HIGH-DENSITY LIPOPROTEIN AND SOMETIMES INCREASED LOW-DENSITY LIPOPROTEIN. THE CHANGES MAY BE VERY MARKED AND COULD HAVE A SERIOUS IMPACT ON THE RISK OF ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE.

How do I store and/or throw out?

If you need to store it at home, talk with your doctor, nurse, or pharmacist about how to store it.

PROTECT FROM LIGHT. Store in carton until contents are used.

ATTENTION: All these products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human and veterinary purposes.